This HTML5 document contains 119 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n16http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n24http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n19http://linked.opendata.cz/resource/drugbank/dosage/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00736/identifier/chebi/
n7http://linked.opendata.cz/resource/drugbank/mixture/
n12http://bio2rdf.org/drugbank:
n30http://linked.opendata.cz/resource/drugbank/drug/DB00736/identifier/wikipedia/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00736/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/patent/
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n15http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n23http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00736/identifier/kegg-drug/
n14http://www.drugs.com/cdi/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00736/identifier/drugbank/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00736/identifier/iuphar/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n29http://linked.opendata.cz/resource/drugbank/drug/DB00736/identifier/guide-to-pharmacology/
n11http://linked.opendata.cz/resource/atc/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00736/identifier/national-drug-code-directory/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00736
rdf:type
n3:Drug
n3:description
A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and zollinger-ellison syndrome. The drug inhibits the H(+)-K(+)-ATPase (H(+)-K(+)-exchanging ATPase) in the proton pump of gastric parietal cells. [PubChem]
n3:dosage
n19:271B528F-363D-11E5-9242-09173F13E4C5 n19:271B5291-363D-11E5-9242-09173F13E4C5 n19:271B5292-363D-11E5-9242-09173F13E4C5 n19:271B529A-363D-11E5-9242-09173F13E4C5 n19:271B529B-363D-11E5-9242-09173F13E4C5 n19:271B5293-363D-11E5-9242-09173F13E4C5 n19:271B5294-363D-11E5-9242-09173F13E4C5 n19:271B529C-363D-11E5-9242-09173F13E4C5 n19:271B5290-363D-11E5-9242-09173F13E4C5 n19:271B5295-363D-11E5-9242-09173F13E4C5 n19:271B5296-363D-11E5-9242-09173F13E4C5 n19:271B5297-363D-11E5-9242-09173F13E4C5 n19:271B5298-363D-11E5-9242-09173F13E4C5 n19:271B5299-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Lind T, Rydberg L, Kyleback A, Jonsson A, Andersson T, Hasselgren G, Holmberg J, Rohss K: Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000 Jul;14(7):861-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10886041
n3:group
investigational approved
n3:halfLife
1-1.5 hours
n3:indication
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
n3:manufacturer
n4:271B5285-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00736 n12:DB00736
dcterms:title
Esomeprazole
adms:identifier
n21:50275 n22:DB00736 n25:0186-6020-01 n26:PA10075 n27:4279 n28:D01984 n29:4279 n30:Esomeprazole
n3:mechanismOfAction
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H<sup>+</sup>/K<sup>+</sup>-ATPase in the gastric parietal cell. By acting specifically on the proton pump, Esomeprazole blocks the final step in acid production, thus reducing gastric acidity.
n3:packager
n4:271B5282-363D-11E5-9242-09173F13E4C5 n4:271B5283-363D-11E5-9242-09173F13E4C5 n4:271B5280-363D-11E5-9242-09173F13E4C5 n4:271B5281-363D-11E5-9242-09173F13E4C5 n4:271B5284-363D-11E5-9242-09173F13E4C5 n4:271B527A-363D-11E5-9242-09173F13E4C5 n4:271B527B-363D-11E5-9242-09173F13E4C5 n4:271B5278-363D-11E5-9242-09173F13E4C5 n4:271B5279-363D-11E5-9242-09173F13E4C5 n4:271B527E-363D-11E5-9242-09173F13E4C5 n4:271B527F-363D-11E5-9242-09173F13E4C5 n4:271B527C-363D-11E5-9242-09173F13E4C5 n4:271B527D-363D-11E5-9242-09173F13E4C5 n4:271B5276-363D-11E5-9242-09173F13E4C5 n4:271B5277-363D-11E5-9242-09173F13E4C5 n4:271B5275-363D-11E5-9242-09173F13E4C5
n3:patent
n18:2346988 n18:5877192 n18:1338377 n18:6428810
n3:routeOfElimination
Approximately 80% of the administered dose of esomeprazole is excreted as metabolites in urine and the remaining 20% is excreted in feces.
n3:synonym
Esomeprazolum (−)-omeprazole Esomeprazol Ésoméprazole (S)-(−)-omeprazole (S)-omeprazole Perprazole
n3:toxicity
Blurred vision, confusion, drowsiness, dry mouth, flushing headache, nausea, rapid heartbeat, sweating
n3:volumeOfDistribution
* 16 L [healthy volunteers]
n10:hasAHFSCode
n17:56-28-36
n3:foodInteraction
Take without regard to meals.
n3:mixture
n7:271B5271-363D-11E5-9242-09173F13E4C5 n7:271B5274-363D-11E5-9242-09173F13E4C5 n7:271B5272-363D-11E5-9242-09173F13E4C5 n7:271B5273-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
97%
n3:salt
n3:synthesisReference
Manne Reddy, "Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof." U.S. Patent US20040167173, issued August 26, 2004.
n23:hasConcept
n24:M0427109
foaf:page
n14:esomeprazole.html n16:esomeprazole.htm
n3:IUPAC-Name
n5:271B52A1-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B52A7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B52A6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B52A3-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B52A4-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B52A5-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B529F-363D-11E5-9242-09173F13E4C5 n5:271B52B7-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B52A0-363D-11E5-9242-09173F13E4C5 n5:271B529D-363D-11E5-9242-09173F13E4C5 n5:271B52B9-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B529E-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n11:A02BC05
n3:H-Bond-Acceptor-Count
n5:271B52AD-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B52AE-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B52A8-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B52A9-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B52AB-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B52AA-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B52AC-363D-11E5-9242-09173F13E4C5
n3:absorption
90%
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
161796-78-7
n3:category
n3:containedIn
n15:271B5289-363D-11E5-9242-09173F13E4C5 n15:271B528A-363D-11E5-9242-09173F13E4C5 n15:271B5287-363D-11E5-9242-09173F13E4C5 n15:271B5288-363D-11E5-9242-09173F13E4C5 n15:271B528C-363D-11E5-9242-09173F13E4C5 n15:271B528D-363D-11E5-9242-09173F13E4C5 n15:271B528E-363D-11E5-9242-09173F13E4C5 n15:271B528B-363D-11E5-9242-09173F13E4C5 n15:271B5286-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B52B3-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B52B5-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B52B6-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B52B8-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B52B2-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B52B1-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B52B4-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B52A2-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B52AF-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B52B0-363D-11E5-9242-09173F13E4C5